Medy-Tox Inc.

Equities

A086900

KR7086900008

Pharmaceuticals

End-of-day quote Korea S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
129,200 KRW -0.08% Intraday chart for Medy-Tox Inc. -0.77% -46.39%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Medy-Tox Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
South Korean Shares Close Marginally Lower on North Korea's Artillery Shells Firing MT
Medy Tox Establishes Subsidiary Luvantas in California MT
Medytox, Inc. Announces the Formation of Luvantas Subsidiary CI
Medytox, Inc. Announces Executive Appointments in Luvantas, Inc CI
Medy-Tox Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Medy-Tox Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
AEON Biopharma, Inc. completed the acquisition of Priveterra Acquisition Corp. from Priveterra Sponsor, LLC, Empyrean Capital Overseas Master Fund, Ltd., managed by Empyrean Capital Partners, LP, Medy-Tox Inc., Daewoong pharmaceutical Co.,Ltd, Strathspey Crown LLC and others in a reverse merger transaction. CI
Medy-Tox Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Medy-Tox Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
AEON Biopharma, Inc. entered into a definitive business combination agreement to acquire Priveterra Acquisition Corp. from Priveterra Sponsor, LLC, Empyrean Capital Overseas Master Fund, Ltd., managed by Empyrean Capital Partners, LP, Medy-Tox Inc., Daewoong pharmaceutical Co.,Ltd, Strathspey Crown LLC and others in a reverse merger transaction. CI
Medy-Tox Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Tranche Update on Medy-Tox Inc.'s Equity Buyback Plan announced on August 17, 2022. CI
Medy-Tox Inc.'s Equity Buyback announced on August 17, 2022, has closed with 41,771 shares, representing 0.70% for KRW 5,084.38 million. CI
Medy-Tox Inc.(KOSDAQ:A086900) dropped from FTSE All-World Index CI
Medy-Tox Inc. announces an Equity Buyback for 41,771 shares. CI
Medy-Tox Inc. authorizes a Buyback Plan. CI
Medy-Tox Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Tranche Update on Medy-Tox Inc.'s Equity Buyback Plan announced on June 7, 2022. CI
Medy-Tox Inc.'s Equity Buyback announced on June 7, 2022, has closed with 39,777 shares, representing 0.66% for KRW 4,574.17 million. CI
Medy-Tox Inc. announces an Equity Buyback for 39,777 shares. CI
Medy-Tox Inc. authorizes a Buyback Plan. CI
Medy-Tox Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Tranche Update on Medy-Tox Inc.'s Equity Buyback Plan announced on February 18, 2022. CI
Medy-Tox Inc.'s Equity Buyback announced on February 18, 2022, has closed with 43,821 shares, representing 0.72% for KRW 5,450.18 million. CI
Chart Medy-Tox Inc.
More charts
Medy Tox Inc is a Korea-based company engaged in the development, manufacture and marketing of biopharmaceuticals. The Company’s main product is type A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. Its products are also used in chin plastic surgeries. The Company provides its products under the brand names of Medytoxin, Neurox, Siax, and Neuramis. In addition, the Company develops and sells medical devices such as injectors under the brand names of Neurajet, Neurafen and others. The Company also engages in technology transfer. The Company distributes its products in domestic and overseas markets such as Japan, China, Russia and Europe.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
129,200 KRW
Average target price
296,000 KRW
Spread / Average Target
+129.10%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. A086900 Stock
  4. News Medy-Tox Inc.
  5. Medy Tox Establishes Subsidiary Luvantas in California